Table 3.
Predictive performance of optical and tissue biomarkers using univariate and multivariate discriminant analyses.
| Parameter | n | Threshold | AUC (Logistic) | AUC (LDA) | Se | Sp | PPV | NPV |
|---|---|---|---|---|---|---|---|---|
| Optical Properties | ||||||||
|
| ||||||||
| StO2-T | 42 | 76.7% | .733 | .719 | 75.0% (42.8 – 93.3%) | 73.3% (53.8 – 87.0%) | 52.9% (28.5 – 76.1%) | 88.0% (67.7 – 96.8%) |
| ctHbO2-T | 42 | 25.4μM | .506 | .536 | 40.0% (22.3 – 77.7%) | 66.7% (47.1 – 82.1%) | 37.5% (16.3 – 64.1%) | 76.9% (55.9 – 90.2%) |
| ctHHb-T | 42 | 7.51μM | .576 | .599 | 66.7% (35.4 – 88.7%) | 53.3% (34.6 – 71.2%) | 36.4% (18.0 – 59.2%) | 80.0% (55.7 – 93.4%) |
| ctTHb-T | 42 | 33.4μM | .419 | .506 | 50.0% (22.3 – 77.7%) | 53.3% (34.6 – 71.2%) | 30.0% (12.8 – 54.3%) | 72.7% (49.6 – 88.4%) |
|
| ||||||||
| StO2-T-N | 33 | −2.51% | .692 | .669 | 81.8% (47.8 – 96.8%) | 59.1% (36.7 – 78.5%) | 50.0% (26.8 – 73.2%) | 86.7% (58.4 – 97.7%) |
| ctHbO2-T-N | 33 | 8.40μM | .545 | .502 | 45.5% (18.1 – 75.4%) | 77.3% (54.2 – 91.3%) | 50.0% (20.1 – 79.9%) | 73.9% (51.3 – 88.9%) |
| ctHHb-T-N | 33 | 2.46 μM | .471 | .450 | 72.7% (39.3 – 92.7%) | 50.0% (28.8 – 71.2%) | 42.1% (21.1 – 66.0%) | 78.6% (48.8 – 94.3%) |
| ctTHb-T-N | 33 | 10.9 μM | .488 | .396 | 36.4% (12.4 – 68.4%) | 77.3% (54.2 – 91.3%) | 44.4% (15.3 – 77.3%) | 70.8% (48.8 – 86.6%) |
| Biomarkers | ||||||||
|
| ||||||||
| ER | 40 | 79.6% | .854 | .860 | 91.7% (59.8 – 99.6%) | 82.1% (62.4 – 93.2%) | 68.8% (41.5 – 87.9%) | 95.8% (76.9 – 99.8%) |
| PR | 40 | 7.61% | .707 | .705 | 83.3% (50.9 – 97.1%) | 67.9% (47.6 – 83.4%) | 52.6% (29.5 – 47.8%) | 90.5% (68.2 – 98.3%) |
| Ki67 | 30 | 48.2% | .672 | .685 | 66.7% (30.9 – 91.0%) | 76.2% (52.4 – 90.9%) | 54.5% (24.6 – 81.9%) | 84.2% (59.5 – 95.8%) |
| Tumor Size | 42 | 2.64cm | .607 | .661 | 75.0% (42.8 – 93.3%) | 63.3% (43.9 – 79.5%) | 45.0% (23.8 – 68.0%) | 86.4% (64.0 – 96.4%) |
| Combination | ||||||||
|
| ||||||||
| StO2-T + ER | 40 | NA | .955 | .933 | 100% (69.9 – 100%) | 85.7% (66.4 – 95.3%) | 75.0% (47.4 – 91.7%) | 100% (82.8 – 100%) |
| StO2-T + PR | 40 | NA | .813 | .802 | 75.0% (42.8 – 93.3%) | 78.6% (58.5 – 91.0%) | 60.0% (32.9 – 82.5%) | 88.0% (67.7 – 96.8%) |
| ctHHb-T + Ki67 | 30 | NA | .773 | .735 | 77.8% (40.2 – 96.1%) | 81.0% (57.4 – 93.7%) | 63.6% (31.6 – 87.6%) | 89.5% (65.5 – 98.2%) |
| StO2-T + Tumor Size | 42 | NA | .681 | .696 | 66.7% (35.4 – 88.7%) | 66.7% (47.1 – 82.1%) | 44.4% (22.4 – 68.7%) | 83.3% (61.8 – 94.5%) |
|
| ||||||||
| StO2-T-N + ER | 32 | NA | .896 | .890 | 90.9% (57.1 – 99.5%) | 90.5% (68.2 – 98.3%) | 83.3% (50.9 – 97.1%) | 95.0% (73.1 – 99.7%) |
| StO2-T-N + PR | 32 | NA | .706 | .710 | 63.6% (31.6 – 87.6%) | 81.0% (57.4 – 93.7%) | 63.6% (31.6 – 87.6%) | 81.0% (57.4 – 93.7%) |
| ctHHb-T-N + Ki67 | 25 | NA | .750 | .765 | 75.0% (35.6 – 95.5%) | 88.2% (62.3 – 97.9%) | 75.0% (35.6 – 95.5%) | 88.2% (62.3 – 97.9%) |
| StO2-T-N + Tumor Size | 33 | NA | .682 | .669 | 72.7% (39.3 – 92.7%) | 77.3% (54.2 – 91.3%) | 61.5% (32.3 – 84.9%) | 85.0% (61.1 – 96.0%) |
|
| ||||||||
| Tumor Size + ER | 40 | NA | .827 | .866 | 91.7% (59.8 – 99.6%) | 77.3% (85.7 – 66.4%) | 73.3% (44.8 – 91.1%) | 96.0% (77.7 – 99.8%) |
| ER + PR | 40 | NA | .811 | .839 | 83.3% (50.9 – 97.1%) | 89.3% (70.6 – 97.2%) | 76.9% (46.0 – 93.8%) | 92.6% (74.2 – 98.7%) |